SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

Volatility: Blue chip stocks are usually less volatile than other stocks.

Pfizer Inc. (NYSE: PFE) delivered a stronger-than-anticipated second-quarter performance, beating analyst estimates and ...

Pfizer Inc. (NYSE: PFE) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 5, the ...

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...

While Pfizer remains on track for an impressive $7.2 billion in cost cuts by the end of 2027, we think the market is more ...

Key Points Non-GAAP EPS was ($0.13), missing the consensus estimate by $0.02 (non-GAAP), due to higher pre-commercialization spending. Research and development expenses fell 48.2% compared to Q2 2024, ...

Pfizer Inc displayed a robust performance in its Q2 2025 earnings call, with significant strides in revenue and research ...

Central to Nxera’s pipeline is its new, wholly owned oral small molecule GLP-1 agonist program, focussed on differentiated chemistry, which is distinct, independent and developed separately from ...

Live Updates Live Coverage Has Ended Tuesday Wrap-up 4:27 pm The Vanguard S&P 500 ETF closed at 577.35 Tuesday, down 0.5%.

Most of its precision oncology products, including Lorbrena, Braftovi, Mektovi, and Talzenna, posted double-digit increases ...

Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...